# SAD/MAD Safety and PK Study of RBN-3143 in Healthy and Atopic Dermatitis Subjects

> **NCT05215808** · PHASE1 · UNKNOWN · sponsor: **Ribon Therapeutics, Inc.** · enrollment: 72 (estimated)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** RBN-3143

## Key facts

- **NCT ID:** NCT05215808
- **Lead sponsor:** Ribon Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-03-07
- **Primary completion:** 2024-06-30
- **Final completion:** 2024-09-30
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2023-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05215808

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05215808, "SAD/MAD Safety and PK Study of RBN-3143 in Healthy and Atopic Dermatitis Subjects". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT05215808. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*